ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2025
Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings.
Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric asthma: positive correlation between platelet-to-HDL-C ratio and blood eosinophil counts.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEosinophilic asthma is associated with frequent exacerbations, but the relevance of peripheral eosinophil count at the time of exacerbation is unknown.
objectiveTo evaluate peripheral eosinophil count during an exacerbation requiring health care utilization and its associations with exacerbation course in adults with asthma.
methodsAdult asthma exacerbations between 2016 and 2023 which resulted in an emergency department visit or hospitalization were identified by International Classification of Diseases, 10th Revision, Clinical Modification diagnosis codes in the Johns Hopkins Asthma Precision Medicine Center of Excellence data repository. Outcomes included probability of admission, maximal level of care, length of stay, and discharge rate. We estimated associations between outcomes and eosinophil count using generalized estimating equations and generalized linear models.
resultsAmong 11,178 asthma exacerbations, 63% had peripheral eosinophil count measured during the encounter before steroid administration, and eosinophilia (≥150 cells/µL) was present in 61% of these. Risk of admission was nonlinearly associated with eosinophil count; exacerbations with eosinophil count of 150 to 300 cells/µL at presentation were least likely to result in admission, whereas those with 30 (odds ratio: 1.39, 95% CI: 1.26-1.54, P < .001) or 1000 cells/µL (odds ratio: 1.55, 95% CI: 1.35-1.79, P < .001) had higher odds of admission. Among inpatient exacerbations (N = 3825), encounters with eosinophil count more than or equal to 300 cells/µL had shorter median length of stay (3.1 vs 2.4 days, P < .001) and higher discharge rate (hazard ratio: 1.34, 95% CI: 1.22-1.48, P < .001) than those without eosinophilia (<150 cells/µL).
conclusionPeripheral eosinophil count is a biomarker for asthma exacerbation severity and duration, offering opportunities for improved assessment and management of asthma exacerbations in acute care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.